Amber Bio develops novel gene editing modalities capable of performing multi-kilobase edits to address previously undruggable patient populations. The company is creating a first-of-its-kind RNA writing platform designed to treat thousands of diverse mutations with a single therapeutic product. This approach moves beyond developing separate therapies for individual mutations in genetic medicine.
Funding
$26M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
- Startup funding source · Source unavailable
- VC website (opens in a new tab)
- Startup funding source · Source unavailable
Founders
Product
Problem
Current genetic medicine approaches often require developing separate therapies for each mutation within a patient population. This approach is not scalable and leaves many patients with previously undruggable conditions.
Solution
Amber Bio is developing an RNA writing platform that enables multi-kilobase gene edits to target diverse mutations in patient populations with previously undruggable conditions. Their approach eliminates the need for separate therapies for each mutation, providing a scalable solution for genetic medicine. The company's platform is designed to be safe and reversible, allowing for larger edits than current gene editing technologies. By studying biological systems and applying biological design principles, Amber Bio aims to create gene therapies that are safe, easy, precise, and affordable.
Target Audience
Amber Bio's primary target audience includes patients with genetic diseases and the biotechnology companies developing genetic medicines.
Features
- RNA writing platform capable of editing thousands of diverse mutations across patients with a single product
- Multi-kilobase edits for addressing previously undruggable conditions
- Designed for safe and reversible gene editing
- Biologically inspired approach leveraging sophisticated biological systems
- Focus on creating gene therapies that are safe, easy, precise, and affordable